RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. - Wikidata - wikimedia - TriplyDB

RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas.

RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas.

http://www.wikidata.org/entity/Q45878050

about

Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo Therapeutic potential of RNA interference against cancer Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration.Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation.Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice.Downregulation of uPAR and cathepsin B induces apoptosis via regulation of Bcl-2 and Bax and inhibition of the PI3K/Akt pathway in gliomas.uPAR/cathepsin B overexpression reverse angiogenesis by rescuing FAK phosphorylation in uPAR/cathepsin B down regulated meningioma.The pathobiology of glioma tumors Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor.Down-regulation of uPAR and cathepsin B retards cofilin dephosphorylation.RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma A deficiency of uPAR alters endothelial angiogenic function and cell morphology.IL-8 and cathepsin B as melanoma serum biomarkers Gene therapy and targeted toxins for glioma.Mechanism of p27 upregulation induced by downregulation of cathepsin B and uPAR in glioma Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells.RNA interference-mediated simultaneous down-regulation of urokinase-type plasminogen activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 human glioma cells uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells.Cellular-based immunotherapies for patients with glioblastoma multiforme.Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway.uPAR and cathepsin B inhibition enhanced radiation-induced apoptosis in gliomainitiating cells.Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target.Epigenetic manipulation of gene expression: a toolkit for cell biologists Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR)Targeting Cathepsin B for Cancer Therapies.Prospects of RNA interference therapy for cancer.Antiprotease therapy in cancer: hot or not?Potential applications of RNA interference technology in the treatment of cancer.Role of cystatins in tumor neovascularization.Knockdown of cathepsin B and uPAR inhibits CD151 and α3β1 integrin-mediated cell adhesion and invasion in glioma RNAi based approaches to the treatment of malignant glioma.Cancer gene therapy targeting angiogenesis: an updated review.Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.Cysteine cathepsins: regulators of antitumour immune response.

P2860

Q22000757-98ECCD36-F3E0-476F-AF80-07202A100314 Q24539093-3BC13F92-B56D-4768-BA13-266E4EE526BE Q28253746-5D5B27AA-97BB-40FE-BCB6-68B7363E56C2 Q28299475-D1E99111-9932-4AF4-852F-2B8AE1783380 Q33357902-CB8473EE-2EED-4667-9C88-A746EE2B3878 Q33641523-C913AD57-595A-4801-98CC-C2BED1DD2DE3 Q33664639-7EEEEC53-9416-455D-9DA9-DE7257047527 Q33742019-26FC6D0B-D77A-470C-8E66-4CC2A573D64C Q33828369-BA5809C4-D04F-47F3-9DCE-EAA37EDD59CF Q33921072-79D684AB-C94F-43D9-B3CB-CEDC98D50449 Q34057949-839B37F9-03D1-4CEC-B594-770137327F18 Q34157183-78ADD08A-30DA-4BA2-85FB-F94DDE28D010 Q34343134-F22B752D-0EA9-4FAB-B16E-5FFA225660B9 Q34601099-B5B46FCF-A837-49E9-A536-DE5BFF4A7572 Q34777224-56A469B8-DFD8-4F3D-AF44-0FE718D25BC2 Q34987834-8D721DA2-5831-4D3B-B1C0-A4EA7A1E2FC1 Q35019176-0ED7CD07-0DA0-4AAE-A8E2-EC544B830215 Q35036032-26F46F67-4D7A-4C49-B580-CF90988CFA5D Q35118933-83BEBA48-9946-4C27-BE8B-8A67CC026FD7 Q35244054-AC651075-A946-421D-95BD-59E92097F74D Q35387417-ECE1227A-D0E0-4F33-8825-CFB3327B9751 Q35630444-E0682E54-FCF9-465D-BEE4-7153C0490416 Q35713784-A15DE1EB-1CD9-4215-AA3D-A0A447C009EA Q35821404-A3C47927-1B81-40A3-BE4D-4859C4C0546B Q35867494-A0E7DEA9-22CE-4A28-857F-C79F707CF2C5 Q36010145-CE7CD82D-4E56-4708-B2C2-9F01126BB636 Q36087869-95E2E5FD-7E5A-4EA1-9646-EB86226CC60D Q36169056-013E5478-8021-45EE-A43D-18D221C87AE4 Q36274412-8D54BD84-200E-418D-B65C-1F235FFE0487 Q36298409-A425C877-E592-460E-BBA2-B8FB71DBF14D Q36326605-63E61CE1-2BF9-47A9-A38A-EE77FEB3F5DC Q36337922-5B2C1F45-CEBE-44FE-AF44-BE9D12CF1502 Q36407244-E1EC3F53-BAF5-4EC9-9EB7-A466B5723E5E Q36429400-2779C17E-388D-4BD3-A83E-6C8FD3EF42DA Q36429583-1A115D47-C06F-46D6-BE45-434D10E5BB19 Q36476417-43D02768-CC42-4F62-95D9-A78039C6780E Q36478665-98F8485E-6F43-4B82-B545-B174C34A3BDC Q36655133-6D511348-7FE1-4BDF-93E2-169175D6BB76 Q36666169-4944C6A4-9241-4D6C-8FAF-24035D46CB8E Q36708304-231287E8-4827-4534-AB7D-2B7AA2048213

P2860

RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas.

http://www.wikidata.org/entity/Q45878050

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

RNAi-mediated inhibition of ca ...... s and tumor growth in gliomas.

@en

RNAi-mediated inhibition of ca ...... s and tumor growth in gliomas.

@nl

type

label

RNAi-mediated inhibition of ca ...... s and tumor growth in gliomas.

@en

RNAi-mediated inhibition of ca ...... s and tumor growth in gliomas.

@nl

prefLabel

RNAi-mediated inhibition of ca ...... s and tumor growth in gliomas.

@en

RNAi-mediated inhibition of ca ...... s and tumor growth in gliomas.

@nl

P1433

Q45878050-F67ED5B5-87C0-424A-A4FF-B0D93D404CF0

P1476

Q45878050-E6BA5C94-BD5B-40E3-AC4F-94293C39E56B

P2093

Q45878050-0EA2A0A0-1B2F-4310-B6AE-80C6E9FA100A

Q45878050-3188B9EB-D91D-4027-9204-24F2847CF399

Q45878050-6A5D2209-7101-4EB8-B1E2-1C15434A132C

Q45878050-ACBBAA68-E4AE-4BDA-BDCB-A2CEEF945C9C

Q45878050-CE7A26CA-7C1C-4911-B1CD-0F338A888459

P2860

Q45878050-0C828245-A9F7-4BE4-97AA-95A900E50042

Q45878050-2A9F3463-5EFA-4BBD-89B9-0F576C36FBBA

Q45878050-2FB5ED71-A384-4EE2-9AEB-FCF38C808058

Q45878050-542D5D8A-F82B-457D-A83F-FA96416E4F10

Q45878050-611B1146-4A66-49CB-8B4E-E7592AF522EA

Q45878050-745DA45E-FA47-4640-B01D-07725BF24205

Q45878050-943636F8-8B98-4BF2-82C6-EB06A272417B

Q45878050-AAFF72FE-991B-43D2-8FAA-35C7AA0FE5A8

Q45878050-BFBF637F-A1F1-4A96-8CC2-F65178957636

Q45878050-D5AB5BBF-CFCC-4128-8F0C-3B7EBF06A701

P2888

Q45878050-152C834B-1066-462C-8B0A-312215F04881

P304

Q45878050-596DAF1D-2847-40ED-B935-FAED100B9CDB

P31

Q45878050-A4653369-C579-45EA-AA25-F89BF63C9FD7

P356

Q45878050-D1BC0572-3FBE-4908-960D-C3C4F769E2C3

P407

Q45878050-82827CE8-0AB4-48BC-84E7-C44BBBAD4F08

P433

Q45878050-F6189F09-C7EA-4162-8C3D-0CF1EC8E9DC3

P478

Q45878050-DD3B833D-36FA-4171-91BD-D663026F12CA

P50

Q45878050-BD462DA5-F1E5-40F6-B76B-0C4E05539DA7

P577

Q45878050-F5CB4F8D-FDB1-4BDE-B046-587C1FCF60EE

P5875

Q45878050-52CAB27D-D8BE-45A4-8377-5989A4F3F9B0

P6179

Q45878050-D53319BE-FE58-4902-91B9-387CEDEA6069

P698

Q45878050-B83A64B7-F605-423B-B653-A405FA0BEAE2

P356

P1433

P1476

RNAi-mediated inhibition of ca ...... is and tumor growth in gliomas

@en

P2093

Dzung H Dinh

http://www.w3.org/2001/XMLSchema#string

Jasti S Rao

http://www.w3.org/2001/XMLSchema#string

Meena Gujrati

http://www.w3.org/2001/XMLSchema#string

Sajani S Lakka

http://www.w3.org/2001/XMLSchema#string

William C Olivero

http://www.w3.org/2001/XMLSchema#string

P2860

Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor.

Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility.

RNA interference: listening to the sound of silence.

The role of plasminogen activators in the regulation of connective tissue metalloproteinases.

Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells.

Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.

Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis.

Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.

The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target.

Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.

P2888

P304

8486-8496

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1207879

http://www.w3.org/2001/XMLSchema#string

P407

P433

52

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Christopher S Gondi

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8336925

http://www.w3.org/2001/XMLSchema#string

P6179

1042963434

http://www.w3.org/2001/XMLSchema#string

P698

15378018

http://www.w3.org/2001/XMLSchema#string